2. Does the increased prevalence in age-related comorbidities, higher inflammatory profiles, etc., in cancer survivors, compared with age-matched cancer-free individuals, represent premature ("accelerated") aging, or does it reflect specific outcomes related to cancer diagnosis and treatment toxicity, and/or side effects? a. Is it possible to elucidate unique "hallmarks of aging" within the context of cancer survivorship? a. Are the primary targets of these drugs leading to accelerated aging?
b. Are the side effects of these drugs leading to accelerated aging?
c. Many of these drugs lead to apoptosis in the targeted cell. Is it possible that there are too many apoptotic bodies for the system to remove, and these produce aging effects? 29. Which advanced statistical analysis techniques hold potential for understanding how brain structure and function change with aging and in response to insults to the brain caused by cancer and cancer treatments?
30. Which models are most appropriate to use to study how brain structure and function change with age and by cancer treatment? 31. Which models describe the resiliency and failure of complex systems? Which are the most appropriate for guiding research related to the interactions of aging processes, cancer, and cancer treatments in determining cognitive aging?
